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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
14.09.2020 Seasonal 
coronavirus 
protective 
immunity is 
short-
lasting 
Nature 
Medicine | Brief 
Communication 
• Duration of acquired 
immunity to SARS-CoV-2 
remains unknown 
• Duration of protection to 
reinfection known from 4 
seasonal coronaviruses may 
reveal common 
characteristics applicable to 
all human coronaviruses 
• From study of healthy 
individuals for more than 35 
years, reinfection with the 
same seasonal coronavirus 
occurred frequently at 12 
months after initial infection, 
coupled with changes in 
levels of virus-specific 
antibodies 
Protective 
immunity 
  
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
 09.09.2020 Predicted 
COVID-19 
fatality rates 
based on 
age, sex, 
comorbidities 
and health 
system 
capacity 
 BMJ Global 
Health | 
Analysis 
• Non-random testing and 
incomplete vital 
registration systems 
render it impossible to 
directly estimate the 
infection fatality rate 
(IFR) in many low- and 
middle-income countries 
• This analysis estimates 
the adjustments required 
to extrapolate estimates 
of the IFR from high-
income to lower-income 
regions 
• Results yield substantial 
differences in the 
predicted IFR across 21 
world regions, however, 
these predictions are 
grounded IFRs from 
countries with advanced 
health systems 
• When adjusting for health 
system capacity, 
difference greatly 
diminish but do not 
entirely erase the 
demography-based 
advantage predicted in 
the lowest income 
settings, with regional 
estimates of the 
predicted C19 IFR 
ranging from 0.37% in 
Western Sub-Saharan 
Africa to 1.45% for 
Eastern Europe 
Infection 
fatality rate, 
age, sex, 
comorbidity, 
health 
system 
capacity 
  
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
 14.09.2020 Quarantine 
alone or in 
combination 
with other 
public 
health 
measures 
to control 
COVID-19: 
a rapid 
review 
Cochrane 
Systematic 
Review | 
Rapid 
• Current evidence is limited 
because most studies on 
C19 are mathematical 
modelling studies that 
make different 
assumptions on important 
model parameters 
• Finding consistently 
indicate that quarantine is 
important in reducing 
incidence and mortality 
during the C19 pandemic, 
although there is 
uncertainty over the 
magnitude of the effect 
• Early implementation of 
quarantine and combing 
quarantine with other 
public health measures is 
important to ensure 
effectiveness 
• Decision makers must 
constantly monitor the 
outbreak and impact of 
measures implemented 
Quarantine, 
public 
health 
measures 
Indirect impact of COVID-19 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
Sept 2020 Results 
Report 
2020 
Global Fund | 
Report 
• Includes a section on ‘Fighting 
HIV, TB and Malaria in the 
Shadow of COVID-19’ 
• From GF biweekly surveys in 
106 countries to monitor the 
impact of C19 on GF 
supported programmes, 
results show that widespread 
disruptions to HIV, TB and 
malaria work as a result of 
both the C19 pandemic itself, 
and the associated public 
health measures. Approx. 
three-quarters of HIV, TB and 
malaria programmes have 
TB, HIV, 
malaria 
been moderately or 
significantly impacted 
• In the early stages of 
lockdown, restrictions on 
gatherings of people and 
transport stoppages have 
been the main reasons 
programme activities have 
been suspended or delayed. 
• As restrictions have eased and 
the pandemic has gained 
momentum, disruptions have 
change and are now a result of 
the impact on health workers 
and the health system, and 
unavoidable fears among the 
general public to go to facilities 
for services. 
• Disruptions to TB, HIV and 
malaria programmes include: 
the reassignment of existing 
medical and laboratory staff 
from these programmes to the 
fight against C19; health 
workers, and especially 
laboratory staff, falling ill with 
C19; C19 related stigma and 
reluctance of health workers to 
attend to people suspected of 
having TB or malaria, which 
have many of the same initial 
symptoms as C19; and people 
unwilling to seek health 
services due to fear of getting 
infected with C19 
Social Science 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
 14.09.2020 The 
impact of 
Covid-19 
on people 
with 
disabilities 
– 
emerging 
findings 
Key findings | 
Narrative 
interviews 
• Key findings from the first 
round of narrative interviews 
(July and August 2020) with a 
diverse group of 40 jobseekers 
with disabilities in Bangladesh, 
Kenya, Nigeria and Uganda 
involved with the Inclusion 
Works programme 
disability  
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
14.09.2020 The lasting misery of coronavirus long-
haulers 
Nature | News 
14.09.2020 Regeneron’s antibody drug added to UK 
Recovery trial of COVID treatments 
Reuters | News 
12.09.2020 Global collaboration for health: rhetoric 
versus reality 
The Lancet | Editorial 
11.09.2020 5 Principles to Guide Adaptive Leadership Harvard Business Review 
10.09.2020 It is time to get serious about vaccine 
confidence 
The Lancet | Comment 
10.09.2020 Curing COVID-19 The Lancet Infectious Diseases | 
Editorial 
10.09.2020 Heidi Larson: shifting the conversation about 
vaccine confidence 
The Lancet | Perspectives 
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
 14.09.2020 A World in Disorder GPMB | 
Annual 
Report 
• A warning from the GPMB in its 
second report that ‘the world 
cannot afford to be unprepared 
again when the next pandemic 
hits’ 
• Five urgent actions are called for: 
responsible leadership; engaged 
citizenship; strong and agile 
systems for health security; 
sustained investment; and robust 
global governance of 
preparedness 
11.09.2020 Diagnostic testing 
for SARS-CoV-2 
WHO | 
Interim 
guidance 
• Updated guidance interim on to 
laboratories and other 
stakeholders involved in 
diagnostics for SARS-CoV-2 
• Includes considerations for 
specimen collection, NAAT 
testing, antigen, antibody 
detection and quality assurance  
11.09.2020 Antigen-detection in 
the diagnosis of 
SARS-CoV-2 
infection using 
rapid 
immunoassays 
WHO | 
Interim 
guidance 
• A new technology has become 
available for detecting SARS-CoV-
2 that is simpler and faster than 
NAAT testing e.g. PCR 
• It relies on direct detection of 
SARS-CoV-2 viral proteins in 
nasal swabs and other respiratory 
sections using a lateral flow 
immunoassay (also called RDT) 
that gives results in less than 30 
minutes 
• But is substantially less sensitive 
that NAAT. They do offer though 
the possibility of rapid, 
inexpensive and early detection of 
the most infectious C19 cases in 
appropriate settings 
• Acknowledging the inadequacy in 
performance and operational 
utility, this interim guidance seeks 
to provide guidance to countries 
on considerations for integration 
into C19 outbreak management 
programmes  
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Dashboards & Trackers 
Cases & deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living evidence & 
policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  
Indonesia  EPPI Centre  WHO International 
Clinical Trials 
Registry Platform 
(ICTRP)  
 FIND SARS-
CoV-2 
Diagnostics: 
performance 
data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre LSHTM  
Johns Hopkins 
University  
European 
CDC  
Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 
WEF    Sierra Leone   Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH   Our World in 
Data: C19 
Testing 
  COVID-19 
Therapeutics 
Accelerator 
 COVID-19 
Vaccine 
Tracker 
Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
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y 
C19 Resource Hubs 
Global  Regional 
& Country 
Academic 
journals & 
Publishers 
Institutes/Centres/
Funders/Other 
Health Topics Social Sciences 
WHO 
COVID-19 
pandemic  
Africa 
CDC 
Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicati
on 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin of 
the WHO 
ICL MRC Centre 
for Global 
Infectious Disease 
Analysis 
Global 
Menstrual 
Collective  
  Disability and 
inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
Cambridge 
University 
Press 
ODI SLH: 
Handwashing 
in low 
resource 
settings 
  Coregroup 
IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell Press Johns Hopkins 
University 
RBM 
Partnership 
  Ethics, health 
systems & 
COVID-19 
UN African 
Academy 
of 
Sciences 
Cochrane  Center for Global 
Development 
 Epidemic 
Preparedness 
Innovations 
  Social 
Development 
Direct C19 blog 
series 
UN Women Africa 
Evidence 
Network 
Elsevier CMMID 
Repository 
    
UNOCHA OCHA 
Southern 
and 
Eastern 
Africa 
COVID-19 
Digest 
Health 
Policy and 
Planning  
Norwegian 
Institute of Public 
Health 
    
UNHCR  South 
African 
Governme
nt 
JAMA 
Network 
Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv 
and 
bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    
World Bank   SAGE 
journals 
 Prevent 
Epidemics  
    
Our World in 
Data 
  Science       
COVID-19 
Narratives by 
David 
Nabarro 
  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  
      
Humanitarian 
OpenStreetM
ap Team 
  Wiley       
Global 
Partnership 
for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global 
Impact Study 
    
  
GISAID           
Online learning & events  
Date Title/URL Online 
learning/event 
Duration Lead 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 
Online 
courses 
Varies WHO 
Available 
now 
Standard precautions: 
Environmental 
cleaning and 
disinfection 
Online course 1 hour WHO 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours per 
week 
Johns Hopkins School 
of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, Modelling 
and Policy 
Online 
learning 
2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online 
learning 
5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online 
learning 
3 hours WHO 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online 
learning 
Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online 
learning 
3 weeks | 4 
hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online 
learning 
3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online 
learning 
5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online 
learning 
Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary 
research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease 
control and health system responses are included. Articles related to tackling the secondary impacts on other 
sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on 
relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
© Crown copyright 2020. 
 
